{"filing":{"accession_number":"0001714899-26-000096","cik":"0001714899","ticker":"DNLI","company_name":"Denali Therapeutics Inc.","form":"8-K","filing_date":"2026-08-06","report_date":"2026-08-06","primary_document":"dnli-20260806.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489926000096/dnli-20260806.htm"},"events":[{"id":25956,"run_id":23570,"accession_number":"0001714899-26-000096","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"summary":"This is a clear earnings release disclosing Denali Therapeutics' second quarter 2026 financial results. The Item 2.02 filing explicitly states \"On August 6, 2026, Denali Therapeutics Inc. (the 'Company') issued a press release announcing its financial results for the second quarter ended June 30, 2026.\" The press release (Exhibit 99.1) reports Q2 2026 net product revenue of $3.6 million, R\u0026D expenses of $97.0 million, SG\u0026A expenses of $36.3 million, and a net loss of $127.6 million, along with cash position and business highlights. This is a material disclosure affecting investor assessment of the company's financial condition and operational performance.","company_name":"Denali Therapeutics Inc.","ticker":"DNLI","filing_date":"2026-08-06","form":"8-K","submitted_at":null,"items":[{"id":26907,"accession_number":"0001714899-26-000096","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"This is a clear earnings release disclosing Denali Therapeutics' second quarter 2026 financial results. The Item 2.02 filing explicitly states \"On August 6, 2026, Denali Therapeutics Inc. (the 'Company') issued a press release announcing its financial results for the second quarter ended June 30, 2026.\" The press release (Exhibit 99.1) reports Q2 2026 net product revenue of $3.6 million, R\u0026D expenses of $97.0 million, SG\u0026A expenses of $36.3 million, and a net loss of $127.6 million, along with cash position and business highlights. This is a material disclosure affecting investor assessment of the company's financial condition and operational performance.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T02:49:54.754307+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":26907,"accession_number":"0001714899-26-000096","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"This is a clear earnings release disclosing Denali Therapeutics' second quarter 2026 financial results. The Item 2.02 filing explicitly states \"On August 6, 2026, Denali Therapeutics Inc. (the 'Company') issued a press release announcing its financial results for the second quarter ended June 30, 2026.\" The press release (Exhibit 99.1) reports Q2 2026 net product revenue of $3.6 million, R\u0026D expenses of $97.0 million, SG\u0026A expenses of $36.3 million, and a net loss of $127.6 million, along with cash position and business highlights. This is a material disclosure affecting investor assessment of the company's financial condition and operational performance.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T02:49:54.754307+00:00","company_name":"Denali Therapeutics Inc.","ticker":"DNLI","filing_date":"2026-08-06"}]}